NO20005397L - Arylkondenserte azapolycykliske forbindelser - Google Patents

Arylkondenserte azapolycykliske forbindelser

Info

Publication number
NO20005397L
NO20005397L NO20005397A NO20005397A NO20005397L NO 20005397 L NO20005397 L NO 20005397L NO 20005397 A NO20005397 A NO 20005397A NO 20005397 A NO20005397 A NO 20005397A NO 20005397 L NO20005397 L NO 20005397L
Authority
NO
Norway
Prior art keywords
aryl condensed
azapolycyclic compounds
condensed azapolycyclic
compounds
aryl
Prior art date
Application number
NO20005397A
Other languages
English (en)
Other versions
NO317300B1 (no
NO20005397D0 (no
Inventor
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20005397L publication Critical patent/NO20005397L/no
Publication of NO20005397D0 publication Critical patent/NO20005397D0/no
Publication of NO317300B1 publication Critical patent/NO317300B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20005397A 1998-04-29 2000-10-26 Arylkondenserte azapolycykliske forbindelser NO317300B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8355698P 1998-04-29 1998-04-29
PCT/IB1999/000617 WO1999055680A1 (en) 1998-04-29 1999-04-08 Aryl fused azapolycyclic compounds

Publications (3)

Publication Number Publication Date
NO20005397L true NO20005397L (no) 2000-10-26
NO20005397D0 NO20005397D0 (no) 2000-10-26
NO317300B1 NO317300B1 (no) 2004-10-04

Family

ID=22179102

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005397A NO317300B1 (no) 1998-04-29 2000-10-26 Arylkondenserte azapolycykliske forbindelser

Country Status (41)

Country Link
US (3) US6462035B1 (no)
EP (1) EP1076650B1 (no)
JP (1) JP2002513007A (no)
KR (1) KR100420423B1 (no)
CN (1) CN1144787C (no)
AP (1) AP1154A (no)
AR (1) AR018596A1 (no)
AT (1) ATE258921T1 (no)
AU (1) AU749831B2 (no)
BG (1) BG64556B1 (no)
BR (1) BR9910058A (no)
CA (1) CA2330576A1 (no)
CO (1) CO5021124A1 (no)
DE (1) DE69914594T2 (no)
DK (1) DK1076650T3 (no)
DZ (1) DZ2778A1 (no)
EA (1) EA003669B1 (no)
ES (1) ES2213354T3 (no)
GT (1) GT199900059A (no)
HR (1) HRP20000731A2 (no)
HU (1) HUP0103340A3 (no)
ID (1) ID26700A (no)
IL (1) IL138917A0 (no)
IS (1) IS5649A (no)
MA (1) MA26623A1 (no)
MY (1) MY133474A (no)
NO (1) NO317300B1 (no)
NZ (1) NZ507035A (no)
OA (1) OA11506A (no)
PA (1) PA8471301A1 (no)
PE (1) PE20000435A1 (no)
PL (1) PL344010A1 (no)
PT (1) PT1076650E (no)
SK (1) SK15952000A3 (no)
TN (1) TNSN99080A1 (no)
TR (1) TR200003122T2 (no)
UA (1) UA61991C2 (no)
UY (1) UY25636A1 (no)
WO (1) WO1999055680A1 (no)
YU (1) YU64400A (no)
ZA (1) ZA992971B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386024T1 (de) 1997-12-31 2008-03-15 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CZ20032814A3 (cs) * 2001-04-20 2004-08-18 Pfizeráproductsáinc Způsob přípravy �Ź@@substituovaných indenů a aryl@kondezovaných azapolycyklických sloučenin
BR0213696A (pt) * 2001-10-31 2004-10-26 Pfizer Prod Inc Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
ATE405574T1 (de) 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
US20060089400A1 (en) * 2002-05-03 2006-04-27 The Vernalis Group Of Companies Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
ES2331245T3 (es) * 2003-07-21 2009-12-28 Pfizer Products Inc. Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
ATE395348T1 (de) * 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
US20060210498A1 (en) * 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives for skin
US20060210497A1 (en) * 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives
DE102005061426A1 (de) * 2005-12-22 2007-07-05 Grünenthal GmbH Substituierte tricyclische Piperidon-Derivate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687937A (en) * 1970-06-23 1972-08-29 Us Of America The 1,5-methano-3-benzazocine derivatives
JPS4914473A (no) * 1972-06-09 1974-02-07
JPS4924968A (no) * 1972-07-01 1974-03-05

Also Published As

Publication number Publication date
EA003669B1 (ru) 2003-08-28
NZ507035A (en) 2003-05-30
CO5021124A1 (es) 2001-03-27
PT1076650E (pt) 2004-05-31
KR20010043143A (ko) 2001-05-25
OA11506A (en) 2004-05-14
IL138917A0 (en) 2001-11-25
WO1999055680A1 (en) 1999-11-04
MY133474A (en) 2007-11-30
ES2213354T3 (es) 2004-08-16
SK15952000A3 (sk) 2002-06-04
ATE258921T1 (de) 2004-02-15
US7122534B2 (en) 2006-10-17
US20030008890A1 (en) 2003-01-09
HK1036453A1 (en) 2002-01-04
CA2330576A1 (en) 1999-11-04
ID26700A (id) 2001-02-01
DE69914594T2 (de) 2004-12-09
TR200003122T2 (tr) 2001-03-21
PE20000435A1 (es) 2000-05-26
HUP0103340A3 (en) 2002-10-28
DK1076650T3 (da) 2004-05-24
EP1076650A1 (en) 2001-02-21
CN1144787C (zh) 2004-04-07
UY25636A1 (es) 2000-02-23
AP9901524A0 (en) 1999-06-30
US6706702B2 (en) 2004-03-16
HRP20000731A2 (en) 2001-06-30
PA8471301A1 (es) 2000-09-29
NO317300B1 (no) 2004-10-04
AP1154A (en) 2003-03-27
US20040167149A1 (en) 2004-08-26
BG64556B1 (bg) 2005-07-29
UA61991C2 (en) 2003-12-15
BG104983A (en) 2001-09-28
NO20005397D0 (no) 2000-10-26
YU64400A (sh) 2003-01-31
DE69914594D1 (de) 2004-03-11
DZ2778A1 (fr) 2005-04-23
CN1298394A (zh) 2001-06-06
AU2951699A (en) 1999-11-16
EA200000996A1 (ru) 2001-06-25
AR018596A1 (es) 2001-11-28
IS5649A (is) 2000-09-29
GT199900059A (es) 2000-10-11
MA26623A1 (fr) 2004-12-20
KR100420423B1 (ko) 2004-03-04
ZA992971B (en) 2000-10-30
TNSN99080A1 (fr) 2005-11-10
BR9910058A (pt) 2000-12-26
JP2002513007A (ja) 2002-05-08
US6462035B1 (en) 2002-10-08
HUP0103340A2 (hu) 2002-02-28
EP1076650B1 (en) 2004-02-04
AU749831B2 (en) 2002-07-04
PL344010A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
LTC1124961I2 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
ATE386024T1 (de) Arylkondensierte azapolycyclische derivate
DE69905038D1 (de) Cyclische boroprolinverbindungen
NO20011745L (no) Forbindelser
NO20004299D0 (no) Organiske forbindelser
FI4209U1 (fi) Uusia yhdisteitä
NO20005006D0 (no) Kalsilytiske forbindelser
NO20005397D0 (no) Arylkondenserte azapolycykliske forbindelser
ATE405580T1 (de) Antithrombotische verbindungen
NO20006662L (no) Fluorfenylresin-forbindelser
NO20020466L (no) Kalsilytiske forbindelser
SE9800626D0 (sv) Compounds
SE9801989D0 (sv) Novel compounds
SE9804211D0 (sv) Novel compounds
SE9804494D0 (sv) Novel compounds
SE9801397D0 (sv) Novel compounds
SE9804493D0 (sv) Novel compounds
SE9800458D0 (sv) Novel compounds
SE9803669D0 (sv) Novel compounds
IDP000021790A (id) Senyawa-senyawa pirolum tersubstitusi
IDP000021799A (id) Senyawa-senyawa pirolum tersubstitusi
SE9803747D0 (sv) New compounds
SE9800511D0 (sv) New compounds